FMS-like tyrosine kinase 3 (FLT3) mutations that involve internal tandem duplications of the juxtamembrane domain-coding sequence are found in 20–30% of patients with acute myeloid leukemia (AML), typically in de novo AML, and are associated with poor clinical outcomes [10–12]. The gene discussed is FLT3; the disease is acute myeloid leukemia.